169 related articles for article (PubMed ID: 38240866)
1. Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience.
D'Oronzo S; Cives M; Lauricella E; Stucci S; Centonza A; Gentile M; Ostuni C; Porta C
Clin Exp Med; 2024 Jan; 24(1):7. PubMed ID: 38240866
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C; Alcaraz A; Bellmunt J; Meseguer C; Gómez-Caamano A; Ribal MJ; Vázquez F; Anido U; Samper P; Esteban E; Álvarez-Ossorio JL; Lara PC; San José LA; Contreras JA; del Alba AG; González-Gragera B; Tabernero AJ; González-Enguita C; Fernández JM; García-Escudero A; Gómez-Veiga F; Méndez MJ; Segarra J; Virizuela JA; Carles J; Lassa A; Calderero V; Constela M; Delgado D; Mañas A; Murias A; Reynes G; Rodriguez B; Rubio G; Sánchez E; Unda M; Solsona E; Martínez-Javaloyas JM; Comet-Batlle J; Quicios C; Martín-Fernández M; Mahillo-Fernández I; Morote J
Br J Cancer; 2013 Jun; 108(12):2565-72. PubMed ID: 23722472
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Patel V
Support Care Cancer; 2022 Feb; 30(2):981-984. PubMed ID: 34373957
[TBL] [Abstract][Full Text] [Related]
6. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
7. Application of bone turnover markers and DXA and QCT in an elderly Chinese male population.
Yuan Y; Zhang P; Tian W; Deng X; Yue R; Ge X; Li X
Ann Palliat Med; 2021 Jun; 10(6):6351-6358. PubMed ID: 34237958
[TBL] [Abstract][Full Text] [Related]
8. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Orita Y; Sugitani I; Takao S; Toda K; Manabe J; Miyata S
Ann Surg Oncol; 2015 Nov; 22(12):4008-13. PubMed ID: 25762482
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.
Hilton JF; Clemons M; Pond G; Zhao H; Mazzarello S; Vandermeer L; Addison CL
J Bone Oncol; 2018 Mar; 10():6-13. PubMed ID: 29204337
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
[TBL] [Abstract][Full Text] [Related]
12. Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial.
Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
J Bone Miner Res; 2022 Jan; 37(1):3-11. PubMed ID: 34585780
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
Miyashita H; Cruz C; Smith C
Support Care Cancer; 2021 Mar; 29(3):1629-1633. PubMed ID: 32747990
[TBL] [Abstract][Full Text] [Related]
14. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Barnadas A; Manso L; de la Piedra C; Meseguer C; Crespo C; Gómez P; Calvo L; Martinez P; Ruiz-Borrego M; Perelló A; Antón A; Codes M; Margelí M; Murias A; Salvador J; Seguí MÁ; de Juan A; Gavilá J; Luque M; Pérez D; Zamora P; Arizcuma A; Chacón JI; Heras L; Martin-Fernández M; Mahillo-Fernández I; Tusquets I
Bone; 2014 Nov; 68():32-40. PubMed ID: 25108081
[TBL] [Abstract][Full Text] [Related]
15. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
[TBL] [Abstract][Full Text] [Related]
18. Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis.
Kundaktepe BP; Sozer V; Kundaktepe FO; Durmus S; Papila C; Uzun H; Simsek G; Gelisgen R
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577803
[No Abstract] [Full Text] [Related]
19. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.
Mazziotti G; Formenti AM; Panarotto MB; Arvat E; Chiti A; Cuocolo A; Dottorini ME; Durante C; Agate L; Filetti S; Felicetti F; Filice A; Pace L; Pellegrino T; Rodari M; Salvatori M; Tranfaglia C; Versari A; Viola D; Frara S; Berruti A; Giustina A; Giubbini R
Endocrine; 2018 Jan; 59(1):90-101. PubMed ID: 29110129
[TBL] [Abstract][Full Text] [Related]
20. Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.
Grey A; Horne A; Gamble G; Mihov B; Reid IR; Bolland M
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32016386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
